Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Theranostics|September 6, 2024
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patientsPeter H J Slootbeek, María Victoria Luna-Velez, Bastiaan M Privé, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 12, 2025
A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancerBastiaan M Privé, Tim M Govers, Bas Israël, et al.
Practical Radiation Oncology|May 4, 2021
68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer VariabilityCédric Draulans, Floris Pos, Robert J Smeenk, et al.
The Lancet. Oncology|June 3, 2023
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trialKarim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Radiology|May 21, 2024
Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate CancerBastiaan M Privé, Bas Israël, Marcel J R Janssen, et al.
Frontiers in Nuclear Medicine|October 2, 2024
An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate CancerBastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, et al.
Lancet (London, England)|September 18, 2024
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trialMichael J Morris, Daniel Castellano, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer PatientsDianne Bosch, Kim J M van der Velden, Irma M Oving, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Cancers|January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective StudyAmina Banda, Bastiaan M Privé, Youssra Allach, et al.
Pageof 10